Search
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS...
Dinoprostone
go.drugbank.com/drugs/DB00917ApprovedInvestigationalIt also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.
Profenamine
go.drugbank.com/drugs/DB00392Approved[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]
Cabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigationalIt was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]
Pyrethrum extract
go.drugbank.com/drugs/DB11087ApprovedThe active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans.
Mixtures: Up and up lice killing maximum strengthGanciclovir
go.drugbank.com/drugs/DB01004ApprovedInvestigationalAn acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Pantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalAs the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists … Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme
Products: PANTOPRAZOL HEXAL K 20MG, PANTOPRAZOL HEXAL K 40MGLenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.